Genentech, Inc.

Xenon Pharmaceuticals Inc.

Array Biopharma Inc.

Silicon Storage Technology, Inc.

F. Hoffmann-la Roche Ag

Genertech, Inc.

Hoffman-laroche, Inc. (us Only)

F. Hoffman-laroche, Ag (ex-us)

Jun M Li

Brian Salvatore Safina

Daniel Fred Ortwine

Jun Liang

Daniel P Sutherlin

Christoph Martin Dehnhardt

Shaoyi Sun

Sultan Chowdhury

Qi Jia

Alla Yurevna Zenova

Birong Zhang

Ivan William Hemeon

Zhiguo Liu

Nicholas Charles Ray

Xiaojing Wang

Sharada Shenvi Labadie

Thilo Focken

Michael Edward Grimwood

Simon Charles Goodacre

Michael Scott Wilson

Jean-Christophe Andrez

Jason R Zbieg

Jiuxiang Zhu

Shannon Marie Decker

Tao Sheng

Andrew D White

James F Blake

Eli M Wallace

Stephen T Schlachter

Rui Xu

Ian S Mitchell

Dengming Xiao

Keith Lee Spencer

Nicholas C Kallan

Josef R Bencsik

Paul Robert Bichler

Christine Chabot

Anna L Banka

Jiangpeng Liao

Chien-An Chen

Tao Wang

Bing-Yan Zhu

Zachary Kevin Sweeney

Matthias Rueth

Thomas E Rawson

Aihe Zhou

Jennafer Dotson

John Wai

Abid Hasan

Ignacio Aliagas-Martin

Wei Gong

Jason S Halladay

Tommy Lai

Frederick Brookfield

Michael Prime

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:  and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and

Heteroaryl estrogen receptor modulators and uses thereof

The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.

Substituted benzamides and methods of use thereof

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, subscript n, ring A, X, L, subscript m, X, R, R, R, R, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables R, subscript n, ring A, X, L, subscript m, X, B, R, R, R, R, Rand Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

N-substituted benzamides and methods of use thereof

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Pyrimidyl cyclopentanes as AKT protein kinase inhibitors

The invention provides compounds having the general formula: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand n are defined herein, compositions including the compounds and method of using the compounds to treat a disease or disorder mediated by the p110 delta isoform of PI3 kinase selected from immune disorders, cancer, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Purine compounds selective for PI3K P110 delta, and methods of use

The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R, R, Rand m are defined herein.

Pentacyclic kinase inhibitors

A high speed bias voltage generating circuit for use with semiconductor devices. The bias voltage generating circuit includes three circuits or circuit portions and which cooperatively control the output voltage and current of the circuit . The standby circuit is active during a standby mode. The standby circuit provides.a stable standby voltage Vout for the circuit , and generates substantially no current in standby mode. The bias circuit is active during a bias mode and provides a stable bias voltage Vout for the circuit . The boost circuit is active during the transition from standby mode to bias mode, and is effective to quickly lower or &ldquo;pull down&rdquo; the output voltage from Vout to Vout .

High speed bias voltage generating circuit

Growing community of inventors

Burlingame, CA, United States of America

Jun M Li